Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2010.228 | Mapping of activating and resistant EGFR mutations in pulmonary adenocarcinoma | Professor Mok Tony |
| 2011.602 | A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR) Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM. IMPRESS- (IRESSATM Mutation Positive Multicentre Treatment Beyond ProgRESsion Study) | Prof. MOK Tony |
| 2011.396 | A Randomized Double Blind Phase 3 Efficacy And Safety Study Of PF-00299804 Versus Erlotinib For The Treatment Of Advanced Non-Small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy | Prof. MOK Tony |
| 2009.331 | Clinical Application of Epidermal Growth Factor Receptor (EGFR) Mutation as Predictive Biomarker for EGFR Tyrosine Kinase Inhibitor (TKI) in Never/Light-Smoker with Adenocarcinoma of Lung | Prof. MOK Tony |
| 2014.257 | A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Patients with Locally Advanced/Metastatic Non Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours are Epidermal Growth Factor Receptor Mutation and T790M Mutation Positive (AURA2) | Prof. MOK Tony |
| 2009.392 | LUX-Lung 3; A randomised, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation | Prof. MOK Tony |
| 2008.248 | A Randomized, Multicenter Phase II Study to Explore Whether Biomarkers Correlate with Treatment Outcome in Chemo-Na・e Patients with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer, Who Receive Treatment with Bevacizumab (at a dose of either 7.5 mg/kg or 15 mg/kg) in Addition to Carboplatin-based Chemotherapy (Gemcitabine or Paclitaxel) | Professor Mok Tony |
| 2008.583 | A randomised, placebo-controlled, double-blind phase III study of intercalated Tarceva_ (erlotinib) or placebo with gemcitabine/platinum as first-line treatment in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) | Prof. MOK Tony |
| 2008.056 | Phase IIb/III Randomized, Double-Blind Trial of BIBW 2992 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Non-Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | Professor Mok Tony |
| 2009.010 | A Phase II Study to Evaluate the Effectiveness of Acupuncture in Treating Chemotherapy Induced Peripheral Neuropathy (CIPN) | Professor Mok Tony |
| 2007.445 | Phase II Study of AZD 2171 in Patients with Recurrent Small Cell Lung Cancer | Professor Mok Tony |
| 2009.595 | A Phase 1B/2 Study of SCH 900105 in Combination with Gefitinib in Asian Subjects with Non-Small Cell Lung Cancer | Professor Mok Tony |
| 2009.248 | A randomized phase II study comparing acupuncture to acupuncture with moxibustion on reduction of chemotherapy-induced neutropenia | Professor Mok Tony |
| 2014.356 | A Phase III, Open Label, Randomized Study of AZD9291 versus Platinum-Based Doublet Chemotherapy for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and whose Tumours harbour a T790M mutation within the Epidermal Growth Factor Receptor Gene (AURA3) | Prof. MOK Tony |
| 2018.434 | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer |
Prof. MOK Tony 莫樹錦教授 |
| 2020.025 | A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations |
Prof. MOK Tony 莫樹錦教授 |
| 2018.394 | The Circulating Cell-free Genome Atlas in Asia (CCGAsia) Study |
Prof. MOK Tony 莫樹錦教授 |
| 2014.487 | A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042) | Prof. MOK Tony S. K. |
| 2009.638 | Phase 2, Open-label, Single Arm Study of the Efficacy and Safety of PF-02341066 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring A Translocation or Inversion Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus | Prof. MOK Tony S. K. |
| 2009.274 | A Phase III, multi-center, placebo-controlled trial of Sorafenib (BAY 43-9006) in patients with relapsed or refractory advanced predominantly non squamous Non-Small Cell Lung Cancer (NSCLC) after 2 or 3 previous treatment regimens | Prof. Mok Tony S. K. |
| 2011.217 | Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus | Prof. MOK Tony S. K. |
| 2008.229 | A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed Alone, and Erlotinib Alone, As Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer | Professor Mok Tony S. K. |
| 2009.024 | A Randomized Phase 2 Trial of PF-00299804 versus Erlotinib for the Treatment of Advanced Non-Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen | Prof. Mok TONY S.K. |
| 2008.260 | A Phase II/III Randomized, Double-Blind Study of Paclitaxel Plus Carboplatin in Combination with Vorinostat (MK-0683) or Placebo in Patients with Stage IIIB (with Pleural Effusion) or Stage IV Non-Small-Cell Lung Cancer (NSCLC) | Professor Mok Tony S.K. |
| 2008.399 | A Phase 2, Open Label, Trial of PF-00299804 in Selected Patients with Untreated Advanced Adenocarcinoma of the Lung | PROF. MOK TONY S.K. |
| 2011.028 | An open-label multi-center study of erlotinib (Tarceva®) as first line therapy until and beyond RECIST progression in NSCLC patients who harbor EGFR mutations | Prof. MOK Tony Shu Kam |
| 2011.179 | A Randomized Phase 3 Study Comparing First-Line Pemetrexed plus Cisplatin (Followed by Gefitinib as Maintenance) with Gefitinib Monotherapy in East Asian (Never Smoker or Light Ex-Smoker) Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer | Prof. Mok Tony Shu Kam |
| 2012.218 | LUX-Lung 7: A randomised, open label Phase IIb Trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung | Prof. MOK Tony Shu Kam |
| 2013.167 | A Multicenter, Open-Label Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung | Prof. MOK Tony Shu Kam |
| 2012.473 | PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS | Prof. MOK Tony Shu Kam |
| 2009.594 | A Phase 2, Multicenter, Randomized Study of Two Different Dose Regimens of Eribulin Mesylate in Combination with Intermittent Erlotinib in Patients with Previously Treated, Advanced Non-Small Cell Lung Cancer | Prof. MOK Tony Shu Kam |
| 2012.422 | A phase II, multicenter, single-arm study of oral LDK378 in adult patients with ALK-activated non-small cell lung cancer previously treated with chemotherapy and crizotinib | Prof. MOK Tony Shu Kam |
| 2013.089 | ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF-00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SUBJECTS WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) ACTIVATING MUTATION(S) | Prof. MOK Tony Shu Kam |
| 2009.393 | INSPIRE - Stimuvax trial In Asian NSCLC Patients: stimulating Immune REsponse A multi-national, double-blind, placebo-controlled, randomized, phase III clinical trial of the cancer vaccine Stimuvax® (L-BLP25 or BLP25 liposome vaccine) in Asian subjects with stage III, unresectable, non-small cell lung cancer (NSCLC) who have demonstrated either stable disease or objective response following primary chemo-radiotherapy | Prof. MOK Tony Shu Kam |
| 2010.390 | Randomized controlled trial of S-1 versus docetaxel in patients with non-small cell lung cancer who have received a platinum-based treatment | Prof. MOK Tony Shu Kam |
| 2012.430 | A Global Phase 3, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer (Asian Phase 3 Study) | Prof. MOK Tony Shu Kam |
| 2022.075 | An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Without Actionable Genomic Alterations |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2021.631 | A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2024.593 | A Phase Ib/II Dose Finding Study Assessing Safety and Efficacy of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination with Carboplatin, Etoposide and Atezolizumab in Induction and with Atezolizumab in Maintenance Phase | Prof. MOK Tony Shu Kam |
| 2017.423 | A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non-Small-Cell Lung Cancer (NSCLC) (POSEIDON) |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2015.238 | A multi-center, open -label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2013.525 | A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib | Prof. MOK Tony Shu Kam |
| 2015.255 | A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (MPDL3280A, ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN+NAB-PACLITAXEL FOR CHEMOTHERAPY-NAIVE PATIENTS WITH STAGE IV NON-SQUAMOUS NON−SMALL CELL LUNG CANCER | Prof. MOK Tony Shu Kam |
| 2015.443 | A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of ATEZOLIZUMAB (anti-PD-L1 antibody) Compared with Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer | Prof. MOK Tony Shu Kam |
| 2016.291 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2014.256 | RANDOMIZED, MULTICENTER, PHASE III, OPEN LABEL STUDY OF ALECTINIB VERSUS CRIZOTINIB IN TREATMENT NAÏVE ANAPLASTIC LYMPHOMA KINASE-POSITIVE ADVANCED NON–SMALL-CELL LUNG CANCER | Prof. MOK Tony Shu Kam |
| 2013.572 | A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF ATEZOLIZUMAB IN PATIENTS WITH PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | Prof. MOK Tony Shu Kam |
| 2016.597 | Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy |
Prof. MOK Tony Shu Kam 莫樹錦教授 |
| 2016.086 | Phase II Study of AZD9291 in patients with advanced stage non-small cell lung cancer following prior EGFR TKI Therapy with EGFR and T790M mutations detected in plasma circulating tumor DNA |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2017.388 | A PHASE II/III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE TARGETED THERAPIES AS TREATMENTS FOR PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING ACTIONABLE SOMATIC MUTATIONS DETECTED IN BLOOD (BFAST: BLOOD FIRST ASSAY SCREENING TRIAL) |
Prof. MOK Tony Shu Kam 莫樹錦 |
Page 171 of 262.